SIBIONICS Introduces GS1 Continuous Glucose Monitoring at G7 Summit 2025 in Brazil

SIBIONICS Showcases GS1 Technology at G7 Summit 2025

SIBIONICS made a significant mark at Brazil's largest hybrid medical education event dedicated to endocrinology and diabetes, taking place during the G7 Summit 2025. The company proudly introduced its cutting-edge Continuous Glucose Monitoring (CGM) technology, named GS1, to an audience of over 100 leading physicians and diabetes experts, amplifying the conversation around smarter healthcare solutions in Brazil.

The event was hosted at Amcham Arena in São Paulo and organized by G7med, bringing together influential voices from the medical community. As an official partner of the Summit, SIBIONICS leveraged the opportunity to not only showcase the GS1 technology but also provide in-depth demonstrations of its application in daily diabetes management.

Participants at the event shared their testimonials on how the GS1 CGM system has transformed their approach to managing diabetes. The presentations highlighted the device’s real-time Bluetooth connectivity, allowing users to monitor their glucose levels directly via their smartphones without needing to manually scan the device. Updates are provided every five minutes, keeping users and their healthcare providers informed and engaged in the management of their health.

One of the standout features of the GS1 system is its capability to sync data even when out of phone range. The sensor continues to store information, and once the connection is restored, all data from the period is synchronized automatically. This ensures a continuous recording of crucial health information, making it a reliable tool for anyone managing diabetes.

The event featured a live demonstration where an expert showcased how to properly wear and apply the CGM device, emphasizing its ease of use and user-friendly design. Attendees left with a deeper understanding of the advancements that GS1 brings to the table, particularly in terms of accessibility and affordability for daily glucose monitoring.

During an engaging Q&A session, clinicians discussed how innovations like GS1 pave the way for a more connected and supportive diabetes management experience. The device is designed to cater to a wide demographic, proving beneficial not just for adults but for children with diabetes as well, reinforcing its role as a versatile solution in the healthcare landscape.

Moreover, the launch of GS1 marks an important milestone in Brazil's healthcare sector, breaking a long-standing stagnation in the diabetes management market. With GS1, SIBIONICS provides healthcare professionals and patients with a renewed choice in managing diabetes effectively, setting a new standard for monitoring and understanding the condition.

As the discussions at the event highlighted, this is more than just about introducing a new medical device. It reflects a broader intent to redefine how diabetes is treated, understood, and managed. The collaboration among industry leaders and healthcare professionals at this year's Summit demonstrated an urgent commitment to innovation in medical care, embracing technology as a core component in facilitating better health outcomes for patients.

For more information about SIBIONICS and its innovative healthcare solutions, visit sibionics.com.br.